Pfizer and OPKO’s Growth Hormone Deficiency Drug Denied by FDA

Jennifer E. Engen

Erik McGregor/LightRocket via Getty Shares of Opko Health plunged more than 16% in premarket trading after the U.S. Food and Drug Administration rejected the once-weekly human growth hormone somatrogon the company co-developed alongside Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients. The FDA issued a Complete Response Letter for the Biologics […]